{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:46:28Z","timestamp":1790063188470,"version":"4.0.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Graphical Abstract<\/jats:title>\n               <jats:p>Proposed framework for foundational and provisional secondary prevention therapy over time in low-risk post-MI patients. Foundational therapies should be considered in all patients without contraindications, while provisional therapies should be considered in selected patients with comorbidities or post-infarction complications. The horizontal time axis proposes duration of therapies and timeframes for pharmacotherapeutic re-assessment, and should be responsive to the temporal evolution of post-MI risk and events. ADP, adenosine diphosphate receptor inhibitors; ASA, acetylsalicylic acid; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; RAAS, renin\u2013angiotensin\u2013aldosterone system; RCT, randomized controlled trials; TG, triglyceride. *Pending guideline recommendations.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehaa1033","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T02:18:47Z","timestamp":1607134727000},"page":"915-918","source":"Crossref","is-referenced-by-count":8,"title":["Learning whether to subtract beta-blockers: it\u2019s about time"],"prefix":"10.1093","volume":"42","author":[{"given":"Sean","family":"van Diepen","sequence":"first","affiliation":[{"name":"Canadian VIGOUR Centre, University of Alberta , Edmonton, Alberta, Canada"},{"name":"Division of Cardiology, Department of Medicine, University of Alberta , Edmonton, Canada"},{"name":"Department of Critical Care Medicine, University of Alberta , Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-3445","authenticated-orcid":false,"given":"Paul W","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Canadian VIGOUR Centre, University of Alberta , Edmonton, Alberta, Canada"},{"name":"Division of Cardiology, Department of Medicine, University of Alberta , Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"2022102514261176400_ehaa1033-B1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.ehj.2004.06.002","article-title":"Task ForceOn Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers","volume":"25","author":"L\u00f3pez-Send\u00f3n","year":"2004","journal-title":"Eur Heart J"},{"key":"2022102514261176400_ehaa1033-B2","first-page":"87","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"40","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102514261176400_ehaa1033-B3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102514261176400_ehaa1033-B4","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(05)67661-1","article-title":"Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"2022102514261176400_ehaa1033-B5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/ehjcvp\/pvy034","article-title":"Effect of oral \u03b2-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis","volume":"5","author":"Dahl Aarvik","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022102514261176400_ehaa1033-B6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/eurheartj\/ehy811","article-title":"CLARIFY investigators. \u03b2-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study","volume":"40","author":"Sorbets","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102514261176400_ehaa1033-B7","first-page":"e344","article-title":"ACC\/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA\/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"2022102514261176400_ehaa1033-B8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cjca.2013.07.680","article-title":"Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease CLARIFY Registry Investigators. Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry","volume":"30","author":"Gandhi","year":"2014","journal-title":"Can J Cardiol"},{"key":"2022102514261176400_ehaa1033-B9","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/eurheartj\/ehaa376","article-title":"Long-term \u03b2-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study","volume":"41","author":"Kim","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102514261176400_ehaa1033-B10","doi-asserted-by":"crossref","first-page":"i4801","DOI":"10.1136\/bmj.i4801","article-title":"\u03b2 blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study","volume":"354","author":"Puymirat","year":"2016","journal-title":"BMJ"},{"key":"2022102514261176400_ehaa1033-B11","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"key":"2022102514261176400_ehaa1033-B12","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa1058","article-title":"Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients in the reperfusion era \u2013 a Danish, nationwide cohort study","volume":"42","author":"Holt","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102514261176400_ehaa1033-B13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2018.10.005","article-title":"BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study","volume":"208","author":"Munkhaugen","year":"2019","journal-title":"Am Heart J"},{"key":"2022102514261176400_ehaa1033-B14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s13063-020-4214-6","article-title":"AD Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial","volume":"21","author":"Kristensen","year":"2020","journal-title":"Trials"},{"key":"2022102514261176400_ehaa1033-B15","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1093\/eurheartj\/ehaa436","article-title":"Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!","volume":"41","author":"Harari","year":"2020","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/9\/915\/46625591\/ehaa1033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/9\/915\/46625591\/ehaa1033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:20:16Z","timestamp":1666718416000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/9\/915\/6082770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,1,11]]},"published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1033","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2021,1,11]]}}}